Full Press Release Details
AVENTIS AND REGENERON ENTER GLOBAL PARTNERSHIP TO DEVELOP AND COMMERICALIZE THE VEGF TRAP INNOVATIVE ANTI-ANGIOGENESIS COMPOUND WILL BE DEVELOPED IN ONCOLOGY AND OPHTHALMOLOGY.
REGN
AVENTIS AND REGENERON ENTER GLOBAL PARTNERSHIP TO DEVELOP AND COMMERICALIZE THE VEGF TRAP INNOVATIVE ANTI-ANGIOGENESIS COMPOUND WILL BE DEVELOPED IN ONCOLOGY AND OPHTHALMOLOGY
Key Takeaway: AVENTIS AND REGENERON ENTER GLOBAL PARTNERSHIP TO DEVELOP AND COMMERICALIZE THE VEGF TRAP INNOVATIVE ANTI-ANGIOGENESIS COMPOUND WILL BE DEVELOPED IN ONCOLOGY AND OPHTHALMOLOGY
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema